公开(公告)号：US20240252627A1

公开(公告)日：2024-08-01

申请号：US18629427

申请日：2024-04-08

申请人： Longeveron Inc.

发明人： Joshua M. HARE ,  Ana Marie LANDIN

IPC分类号： A61K39/39 ,  A61K35/28 ,  A61K38/00 ,  A61K39/00 ,  A61K39/145 ,  A61P31/16

CPC分类号： A61K39/39 ,  A61K35/28 ,  A61K39/145 ,  A61P31/16 ,  A61K38/00 ,  A61K2039/515 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/555 ,  A61K2039/55588 ,  A61K2039/70

摘要： The present invention provides a method of enhancing an immune response to a vaccine by administering a vaccine and a population of isolated allogeneic human mesenchymal stem cells. The present invention also provides kits comprising a vaccine in a first container and a population of isolated allogeneic human mesenchymal stem cells in a second container.

公开(公告)号：US12016973B2

公开(公告)日：2024-06-25

申请号：US16339674

申请日：2017-10-05

申请人： ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

发明人： Klearchos K. Papas

IPC分类号： A61L27/54 ,  A61F2/02 ,  A61K35/12 ,  A61K35/13 ,  A61K38/19 ,  A61K39/39 ,  A61L27/36 ,  A61P35/00 ,  A61K9/00 ,  A61K39/00

CPC分类号： A61L27/54 ,  A61F2/022 ,  A61K35/12 ,  A61K35/13 ,  A61K38/19 ,  A61K39/39 ,  A61L27/3683 ,  A61P35/00 ,  A61K9/0024 ,  A61K2039/515

摘要： Methods, systems, and devices for enhancing cancer immunotherapy featuring co-transplantation of encapsulated xenogeneic cells with separately encapsulated autologous or allogeneic cells, e.g., autologous or allogeneic tumor cells. For example, both a first cellular transplantation device housing a patient's own tumor cells and a second cellular transplantation device housing xenogeneic cells may be implanted into a patient. The presence of the xenogeneic cells elicits an enhanced immune response, e.g., the xenogeneic cells will draw in a large number of immune cells. Shed tumor antigens from the first cellular transplantation may then be taken up by the immune cells that were drawn to the xenogeneic cells. This will generate an anti-tumor immune response that is amplified relative to a response elicited by the encapsulated tumor cells alone.

公开(公告)号：US11975068B2

公开(公告)日：2024-05-07

申请号：US16075276

申请日：2017-02-02

申请人： Longeveron Inc.

发明人： Joshua M. Hare ,  Ana Marie Landin

IPC分类号： A61K39/39 ,  A61K35/28 ,  A61K38/00 ,  A61K39/00 ,  A61K39/145 ,  A61P31/16

CPC分类号： A61K39/39 ,  A61K35/28 ,  A61K39/145 ,  A61P31/16 ,  A61K38/00 ,  A61K2039/515 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/555 ,  A61K2039/55588 ,  A61K2039/70 ,  A61K35/28 ,  A61K2300/00

摘要： The present invention provides a method of enhancing an immune response to a vaccine by administering a vaccine and a population of isolated allogeneic human mesenchymal stem cells. The present invention also provides kits comprising a vaccine in a first container and a population of isolated allogeneic human mesenchymal stem cells in a second container.

公开(公告)号：US11883429B2

公开(公告)日：2024-01-30

申请号：US17075721

申请日：2020-10-21

申请人： Enlivex Therapeutics RDO Ltd

发明人： Dror Mevorach ,  Shai Novik

IPC分类号： A61K35/15 ,  A61K39/00 ,  C12N5/078 ,  A61K35/17 ,  A61P37/00 ,  A61K9/00 ,  A61K35/12

CPC分类号： A61K35/15 ,  A61K9/0019 ,  A61K35/17 ,  A61K39/0008 ,  A61P37/00 ,  C12N5/0634 ,  A61K2035/122 ,  A61K2039/515 ,  A61K2039/58 ,  C12N2501/39

摘要： Cell preparations comprising a pooled and enriched, mononuclear apoptotic cell population, and a method of preparing this cell preparation are described. The pooled mononuclear apoptotic cell preparation may be obtained from pooled, allogeneic white blood cell fractions that are pooled prior to or following induction of apoptosis. Further, described herein are methods of use of these pooled apoptotic cell preparations for treating an immune disease, an inflammatory disease, an autoimmune disease, or infertility in a subject. For example, a pooled apoptotic cell preparation may be used to treat graft versus host disease (GVHD) in an allogeneic subject.

公开(公告)号：US11857612B2

公开(公告)日：2024-01-02

申请号：US18066648

申请日：2022-12-15

申请人： NantCell, Inc.

发明人： Patrick Soon-Shiong

IPC分类号： A61K39/04 ,  A61K35/15 ,  A61K39/39 ,  A61K39/00

CPC分类号： A61K39/04 ,  A61K35/15 ,  A61K39/00114 ,  A61K39/001119 ,  A61K39/39 ,  A61K2039/515 ,  A61K2039/585

摘要： Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin (BCG).

公开(公告)号：US11844814B2

公开(公告)日：2023-12-19

申请号：US16986755

申请日：2020-08-06

申请人： The General Hospital Corporation

发明人： Denise L Faustman

IPC分类号： A61K39/00 ,  A61K35/17 ,  C12N5/0783 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K39/00 ,  C07K16/2878 ,  C12N5/0637 ,  A61K2039/515 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2501/04 ,  C12N2501/2302 ,  C12N2501/25 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/60

摘要： The invention features methods of producing compositions enriched in Tregs and methods for treating immunological disorders using these compositions. The invention also features methods for producing compositions enriched in lymphocytes and depleted of Tregs and the use of these compositions in the treatment of proliferative disorders.

公开(公告)号：US20230312658A1

公开(公告)日：2023-10-05

申请号：US18067525

申请日：2022-12-16

申请人： Centivax, Inc.

发明人： Jacob E. Glanville

IPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/21 ,  A61K38/46 ,  G16B30/10 ,  A61K39/00 ,  G16C20/60 ,  C12N7/00 ,  G16B35/00 ,  G16B20/30 ,  G16B30/00 ,  G16B35/10 ,  G16B20/00

CPC分类号： C07K14/005 ,  A61K38/46 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/21 ,  C12N7/00 ,  G16B20/30 ,  G16B30/00 ,  G16B30/10 ,  G16B35/00 ,  G16B35/10 ,  G16C20/60 ,  A61K2039/515 ,  A61K2039/5154 ,  A61K2039/53 ,  A61K2039/575 ,  A61K2039/70 ,  C12N2740/16034 ,  C12N2740/16071 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12Y306/05002 ,  G16B20/00

摘要： The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.

公开(公告)号：US20230285463A1

公开(公告)日：2023-09-14

申请号：US18188380

申请日：2023-03-22

申请人： Juno Therapeutics, Inc.

发明人： Mark J. GILBERT

IPC分类号： A61K35/17 ,  C07K16/28 ,  A61K45/06 ,  B65D25/20

CPC分类号： A61K35/17 ,  C07K16/2803 ,  A61K45/06 ,  B65D25/205 ,  A61K2039/515

摘要： Provided are methods for administering multiple doses of cells, such as T cells, to subjects for cell therapy. Also provided are compositions and articles of manufacture for use in the methods. The cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods generally involve administering a first and at least one consecutive dose of the cells. Timing of the doses relative to one another, and/or size of the doses, in some embodiments provide various advantages such as lower or reduced toxicity and improved efficacy, for example, due to increased exposure of the subject to the administered cells. In some embodiments, the first dose is a relatively low dose, such as one that reduces tumor or disease burden, thereby improving the efficacy of consecutive or subsequent doses, and the consecutive dose is a consolidating dose.

公开(公告)号：US11674121B2

公开(公告)日：2023-06-13

申请号：US17665130

申请日：2022-02-04

申请人： The Regents of the University of California

发明人： Richard Klemke ,  Huawei Wang

IPC分类号： C12N5/0775 ,  A61K9/00 ,  A61K35/28 ,  C12N15/85 ,  A61K38/20 ,  A61K39/00 ,  A61K35/12 ,  A61K39/215

CPC分类号： C12N5/0662 ,  A61K9/0019 ,  A61K35/12 ,  A61K35/28 ,  A61K38/2066 ,  A61K39/001102 ,  A61K39/215 ,  C12N15/85 ,  A61K2039/515 ,  A61K2039/545 ,  C12N2501/999 ,  C12N2510/00

摘要： Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.

公开(公告)号：US20190201511A1

公开(公告)日：2019-07-04

申请号：US16239346

申请日：2019-01-03

申请人： BATU BIOLOGICS, INC.

发明人： Samuel C. Wagner ,  Thomas E. Ichim ,  Santosh Kesari

IPC分类号： A61K39/00

CPC分类号： A61K39/0006 ,  A61K2039/515 ,  A61K2039/55 ,  A61K2039/572 ,  A61K2039/575

摘要： Disclosed are methods of preventing pregnancy through induction of immunological responses through vaccination with placental extracts and products associated with placentation. In one particular embodiment an immune response is triggered towards pregnancy associated neoangiogenesis through administration of placental endothelial cells capable of triggering immunity. In other embodiments the process of replicating immunological events associated with pregnancy failure are recapitulated by stimulation of immunity to antigens such as VEGFR-1, VEGFR-2, CD105, FGF1-R, Integrin αvβ3, and CD-248.